- Home
- TMCR vs XFOR Comparison
TMCR vs XFOR Comparison
Compare TMCR & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMCR | XFOR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.0M | 377.3M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TMCR | XFOR |
|---|---|---|
| Price | $6.40 | $4.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 59.8K | ★ 696.9K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $5.14 | $2.69 |
| 52 Week High | $8.75 | $4.83 |
Technical Indicators
Market Signals| Indicator | TMCR | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 50.85 |
| Support Level | $5.42 | $3.54 |
| Resistance Level | $6.59 | $4.51 |
| Average True Range (ATR) | 0.76 | 0.27 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 48.13 | 31.05 |
Price Performance
Historical ComparisonAbout TMCR The Metals Royalty Company Inc. Common Stock
The Metals Royalty Co Inc is engaged in the acquisition and management of critical metals and mineral royalties, streams, and other similar interests. It is focused on providing capital to support mineral security and independence in North America in support of accelerating domestic industry growth, including energy, defense, and re-industrialization. The company derives royalty income from its business activities.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.